What is Glytec?
Founded in 2006 and headquartered in Waltham, Massachusetts, Glytec is dedicated to providing innovative glycemic management solutions for individuals managing diabetes worldwide. The company's technology aims to improve patient outcomes and streamline clinical workflows in healthcare settings. The recent major strategic investment signals strong confidence from backers in Glytec's mission and its potential for growth within the healthcare technology sector.
How much funding has Glytec raised?
Glytec has raised a total of $21M across 2 funding rounds:
Debt
$9M
Private Equity
$12M
Debt (2021): $9M with participation from Silicon Valley Bank
Private Equity (2021): $12M led by Savitr Capital
Key Investors in Glytec
Silicon Valley Bank
Silicon Valley Bank is a financial institution offering a wide range of banking and investment services, often supporting technology and healthcare companies through various stages of growth.
Savitr Capital
Savitr Capital is an investment firm that specializes in direct capital investments, focusing on complex situations and partnering with management for long-term value creation and growth.
What's next for Glytec?
With a substantial enterprise-level funding context, Glytec is poised for significant expansion and further development of its glycemic management solutions. This strategic backing will likely fuel advancements in their product offerings, enhance market penetration, and potentially support research into new therapeutic approaches for diabetes management. The company's trajectory suggests a focus on scaling operations and solidifying its role as a key player in the digital health and diabetes care landscape.
See full Glytec company page
